474-87-3

Basic information

• Product Name: ,9-Dehydroestrone
• Synonyms: ,9-Dehydroestrone;3-Hydroxy-estra-1,3,5(10),8-tetraen-17-one;8,9-Dehydroestrone;-Dehydroestrone;-Isoequilin;8-Isoequilin;8,9-Dehydroestrone-d2;Delta-8,9-Dehydro Estrone
• CAS NO: 474-87-3
• Molecular Formula: C₁₈H₂₀O₂
• Molecular Weight: 268.3502
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
• Mol File: 474-87-3.mol
• Article Data: 2

Chemical Properties

• Melting Point: 219-221°C
• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Ethanol (Slightly), Methanol (Slightly)
• PKA: pKa 10.17±0.04(H2O t=23±2 ) (Uncertain)
• CAS DataBase Reference: ,9-Dehydroestrone(CAS DataBase Reference)
• NIST Chemistry Reference: ,9-Dehydroestrone(474-87-3)
• EPA Substance Registry System: ,9-Dehydroestrone(474-87-3)

Safety Data

• Hazardous Substances Data: 474-87-3(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 474-87-3 differently. You can refer to the following data:
1. A metabolite of Equilin steroid.
2. A metabolite of Equilin steroid

Upstream product

• 474-86-2 equilin 
• 23392-52-1 rac-3,17-β-Dihydroxy-oestra-1,3,5(10),8-tetraen 
• 2919-30-4 (+/-)-3-Methoxy-18-methylestra-1,3,5(10),8-tetraen-17β-ol 
• 1971-84-2 5-m-acetoxyphenylpent-1-yne 
• 765-69-5 2-Methylcyclopentane-1,3-dione 
• 33818-63-2 3-Hydroxy-oestrapentaen-(1,3,5⁽¹⁰⁾,8,14)-on-⁽¹⁷⁾ 
• 152584-46-8 6-(tert-butyldimethylsilyloxy)-3,4-dihydronaphthalen-1(2H)-one 
• 3470-50-6 6-Hydroxy-1-tetralone 
• 350695-33-9 3-tert-butyldimethylsiloxy-8,9-dehydroestrone 

Relevant articles and documents

Synthesis of ring B unsaturated estriols. Confirming the structure of a diagnostic analyte for Smith-Lemli-Opitz syndrome

(Equation presented) Brief partial syntheses are described for ring B unsaturated estriols, which are candidate metabolites diagnostic for Smith-Lemli-Opitz syndrome prenatally. These steroids are also likely metabolites of the Premarin preparation used in estrogen replacement therapy. Equilin (8) was converted in three steps to 7-dehydroestriol, which was isomerized to 8-dehydroestriol. The simplicity of the transformations belies the lability of these previously inaccessible metabolites and their synthetic precursors.